The study, led by Prasanth Viswanathan and colleagues, focused on a protein called myeloid cell leukemia-1, or MCL1. MCL1 belongs to a family of proteins that act as molecular bodyguards, blocking the self-destruct program known as apoptosis. It is an oncogene, meaning that when it is amplified or overactive it drives cancer, and tumors with high MCL1 levels are notoriously resistant to chemotherapy. Because of its clinical importance, MCL1 inhibitors are already being developed and tested in trials, making it an attractive target for drug designers. Previous work had shown that PEL cell lines, the laboratory models of this lymphoma, cannot survive without MCL1, but the details of how MCL1 protects these virus-transformed cells remained murky.

To dig deeper, the team turned to a systems biology approach, mapping the web of genetic interactions surrounding MCL1 in PEL cells. This unbiased strategy surfaced a surprise: MCL1 appeared to function in the same pathway as a protein called MARCHF5, a membrane-anchored E3 ubiquitin ligase residing in the mitochondria. MARCHF5 was not an obvious suspect. It is best known for maintaining mitochondrial homeostasis and for tuning antiviral signaling pathways, not for regulating apoptosis. The genetic interaction hinted, however, that the two proteins cooperate in keeping PEL cells alive, and the researchers set out to test that idea directly.

The first experiment was decisive. Using CRISPR gene editing, the team knocked out the MARCHF5 gene in PEL cell lines. Even though MCL1 was still present and functional, the loss of MARCHF5 triggered a significant increase in apoptosis. In other words, MCL1 alone was not enough to keep the cells alive; they also needed MARCHF5. This was a striking result because it established that a mitochondrial ubiquitin ligase, a protein class usually discussed in the context of mitochondrial quality control, plays an essential anti-apoptotic role in these virus-transformed tumor cells.

MARCHF5 is an enzyme, and enzymes can often be disabled by breaking their catalytic machinery. The researchers probed which activities of MARCHF5 were required for its survival function. Two features proved essential: its E3 ligase activity, the enzymatic ability to attach ubiquitin tags to target proteins, and its capacity to dimerize, or pair up with another MARCHF5 molecule. When either of these activities was disrupted, the protein could no longer protect PEL cells from apoptosis. This mechanistic detail matters because it suggests the survival function of MARCHF5 is not a passive structural role but an active enzymatic process, one that could in principle be targeted with drugs.

What was MARCHF5 actually doing? The clue came from an unexpected direction. When the researchers removed MARCHF5, or when they treated the cells with inhibitors of the 26S proteasome, the cellular machine that destroys ubiquitin-tagged proteins, one particular protein accumulated: NOXA. NOXA is a pro-apoptotic member of the same protein family as MCL1, and its job is essentially to antagonize MCL1 and push the cell toward self-destruction. Intriguingly, the levels of MCL1 itself did not change under these conditions. Instead, MARCHF5 appeared to be keeping NOXA in check, and without MARCHF5 the lethal signal built up unchecked.

The team then asked whether NOXA was truly the pro-apoptotic signal that MCL1 and MARCHF5 exist to neutralize. Several lines of evidence converged on that conclusion. Endogenous reciprocal co-immunoprecipitation experiments, which pull protein complexes out of cells without artificial tagging, showed that MARCHF5 and NOXA are found together in the same protein complex, consistent with a direct physical relationship. Even more telling, when the researchers knocked out the NOXA gene on its own, the PEL cells gained a fitness advantage, suggesting that NOXA exerts a constant, damaging pressure on these tumor cells that must be continuously suppressed for survival.

The most convincing test came from a genetic rescue experiment. If NOXA accumulation is the reason that MARCHF5-deficient cells die, then deleting NOXA should save them. That is exactly what the researchers observed: knocking out NOXA restored cell viability in PEL lines that had lost MARCHF5. Together, these experiments provide the mechanistic link that underlies the original genetic interaction between MCL1 and MARCHF5. The model that emerges is elegant: MARCHF5, using its ubiquitin ligase activity, induces the degradation of NOXA, the natural enemy of MCL1, thereby reinforcing MCL1’s pro-survival function and allowing the KSHV-transformed cells to evade apoptosis.

This finding adds a new layer to the biology of KSHV-associated malignancies. Primary effusion lymphoma arises when the virus reprograms B cells into rapidly proliferating, apoptosis-resistant tumor cells that typically grow as lymphomas in body cavities. The virus achieves this in part by manipulating the host cell’s apoptotic machinery, and the MCL1-MARCHF5 axis now appears to be a central node in that manipulation. The fact that both proteins are required, and that they act through a defined substrate, NOXA, gives researchers a clearer picture of the survival circuitry that these tumors depend on. It also raises the possibility that similar cooperation between MCL1 and mitochondrial ubiquitin ligases operates in other cancers where MCL1 is amplified.

From a therapeutic standpoint, the implications are considerable. MCL1 inhibitors are an active area of drug development precisely because MCL1 amplification drives chemoresistance in many cancers. The new work suggests that combination therapies targeting both MCL1 and MARCHF5, or approaches that prevent MARCHF5 from degrading NOXA, could be more effective than hitting either protein alone, since the two oncogenes reinforce each other’s function. Disabling MARCHF5’s ligase activity would strip away one of the defenses that keeps NOXA suppressed, potentially sensitizing tumor cells to MCL1 inhibition or to existing chemotherapy regimens. As the authors note, this newly appreciated interaction between the MCL1 and MARCHF5 oncogenes may prove useful in improving the design of combination therapies for KSHV malignancies, offering a rational strategy against a cancer that has so far proven difficult to treat.

Subject of Research: How the mitochondrial ubiquitin ligase MARCHF5 cooperates with MCL1 to inhibit apoptosis in KSHV-transformed primary effusion lymphoma cells

Article Title: The Mitochondrial ubiquitin ligase MARCHF5 cooperates with MCL1 to inhibit Apoptosis in KSHV-transformed primary effusion lymphoma cell lines

Article References: Viswanathan, P., Bersonda, J. R., Gill, J., Navarro, A., Farrar, A. C., Caldarera, T., Murphy, A., Dunham, D., Boehme, K. W., & Manzano, M. (2026). The mitochondrial ubiquitin ligase MARCHF5 cooperates with MCL1 to inhibit apoptosis in KSHV-transformed primary effusion lymphoma cell lines. PLOS Pathogens, 22(10), e1014665. https://doi.org/10.1371/journal.ppat.1014665

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014665

Keywords: KSHV, primary effusion lymphoma, MCL1, MARCHF5, NOXA, apoptosis, ubiquitin ligase, mitochondria, CRISPR, oncogene, viral oncology, combination therapy

The Notch pathway is one of the most evolutionarily conserved signaling systems in multicellular organisms. In mammals it comprises four transmembrane receptors, NOTCH1 through NOTCH4, and five membrane-bound ligands of the Delta-like and Jagged families. Signaling is unusual in that it does not rely on a second-messenger cascade: when a ligand on a neighboring cell engages a Notch receptor, the receptor undergoes sequential cleavage, first by ADAM-family metalloproteinases and then by the γ-secretase complex. This releases the Notch intracellular domain (NICD), which translocates to the nucleus and binds the DNA-associated transcription factor CSL, together with the coactivator Mastermind-like (MAML), to switch on target genes. Foremost among these are the Hairy and Enhancer of Split (HES) and HEY family transcriptional repressors, which in turn control genes governing proliferation, differentiation, and survival.

Because Notch sits at the helm of decisions about when cells divide, when they differentiate, and when they die, even modest dysregulation can be dangerous. The review emphasizes that abnormal Notch activity has been implicated in cell proliferation, resistance to apoptosis, maintenance of stem-like cell populations, epithelial–mesenchymal transition (EMT), and immune evasion. In normal tissue these processes are carefully balanced; in cancer they are the engine of tumor growth and spread. The authors’ central thesis is that oncoviruses exploit this pathway deliberately, co-opting its transcriptional output to create a cellular environment favorable to viral persistence and, ultimately, malignant transformation.

HPV provides one of the clearest examples. The viral oncoproteins E6 and E7, which drive degradation of the tumor suppressors p53 and pRB, also interact with Notch signaling in ways that shift the pathway’s effects. Notch signaling in HPV-infected keratinocytes can cooperate with viral gene expression to sustain proliferation and block terminal differentiation—the very process the virus must arrest to complete its life cycle. The review notes that HPV-positive lesions show altered expression of Notch receptors and ligands, and that the interplay between E6/E7 and NICD-dependent transcription blurs the line between the productive viral life cycle and neoplastic progression, particularly in cervical carcinogenesis.

HTLV-1, the causative agent of adult T-cell leukemia/lymphoma (ATLL), takes a different route. Its trans-activator protein Tax is a potent manipulator of host transcription factors, and the review describes how Tax-driven activation of NF-κB and AP-1 converges with Notch signaling to keep infected T cells in a proliferative, apoptosis-resistant state. The HTLV-1 basic leucine zipper factor (HBZ), expressed from the antisense strand, further entrenches this program, supporting the survival and expansion of leukemic clones. The same virus is also associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), underscoring that Notch manipulation has consequences beyond cancer.

Among the herpesviruses, EBV and KSHV display especially intricate relationships with Notch. EBV latency proteins, including the Epstein–Barr nuclear antigens (EBNAs) and latent membrane proteins (LMPs), modulate Notch receptor processing and downstream transcription; LMP1 and LMP2A signaling intersects with NICD-mediated gene activation in nasopharyngeal carcinoma and EBV-associated lymphoid malignancies. KSHV, the etiologic agent of Kaposi’s sarcoma, deploys its own arsenal: the latency-associated nuclear antigen (LANA), the viral FLICE-inhibitory protein (vFLIP), and the viral G protein-coupled receptor (vGPCR) each contribute to Notch pathway activation, fostering the angiogenesis, inflammation, and cell survival that characterize the tumor. The replication and transcription activator (RTA), which controls the viral lytic switch, adds a further layer of regulation linking viral life cycle dynamics to host signaling.

The hepatitis viruses illustrate that even viruses not conventionally classed as DNA-tumor viruses participate in this crosstalk. HBV’s X protein (HBx) promotes Notch activation in hepatocytes, contributing to the proliferative and survival signals that underlie hepatocellular carcinoma, while HCV proteins engage the pathway in ways that reinforce chronic inflammation and fibrogenic progression toward malignancy. In both cases, the review suggests that Notch dysregulation acts as a bridge between chronic viral injury and the molecular events of carcinogenesis, potentially offering biomarkers that distinguish progressing lesions from indolent disease.

A recurring theme across all six viruses is context dependence. Notch can behave as an oncogene in some tissues and as a tumor suppressor in others, and the review stresses that the outcome of viral manipulation depends on cell type, the differentiation state of the infected cell, and which receptors and ligands are expressed. Additional layers of control—including microRNAs, long non-coding RNAs, the E3 ubiquitin ligase FBXW7 that targets NICD for degradation, and fringe glycosyltransferases such as Manic Fringe that modify ligand–receptor affinity—determine where the signaling dial sits. Viruses appear to nudge these layers simultaneously, producing a coherent pro-tumor transcriptional state rather than a single wholesale switch.

The therapeutic implications are significant. γ-secretase inhibitors (GSIs), originally developed for Alzheimer’s disease and already tested in Notch-driven T-cell leukemias, emerge as a class of compounds that could, in principle, sever the viral exploitation of the pathway. The review also points toward Notch-related biomarkers for early detection and risk stratification in virus-associated cancers, and toward combination strategies in which antiviral therapy is paired with pathway-targeted agents. However, the authors caution that Notch’s dual roles and its importance in normal stem cell maintenance demand careful dosing and tissue-specific approaches.

The review closes by flagging the field’s unresolved questions: the precise order in which viral proteins and Notch activation act during multi-step carcinogenesis, the contribution of Notch to immune evasion in virally infected tissue, and whether Notch signatures can reliably predict transformation in premalignant lesions. What is already clear, the authors conclude, is that deeper mechanistic understanding of virus–Notch crosstalk could reshape basic research on viral carcinogenesis, yield diagnostic biomarkers, and guide the next generation of targeted antiviral and anti-cancer therapies. As the list of virus-associated malignancies continues to grow, the Notch pathway looks increasingly like common ground on which these diverse pathogens meet.

Subject of Research: Dysregulation of the Notch signaling pathway by human oncogenic viruses in carcinogenesis

Article Title: Oncogenic human viruses and notch signaling: a focus on key dysregulation within the NOTCH pathway

Article References: Oncogenic human viruses and notch signaling: a focus on key dysregulation within the NOTCH pathway. (n.d.). https://doi.org/10.1186/s12985-026-03324-w

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03324-w

Keywords: Notch signaling, oncogenic viruses, HPV, HTLV-1, EBV, KSHV, HBV, HCV, carcinogenesis, NICD, gamma-secretase inhibitors, EMT

The team began by searching for cellular partners of vIRF3 in lymphatic endothelial cells using immunoprecipitation followed by mass spectrometry. Among the proteins that specifically co-purified with the viral factor was a polypeptide of roughly sixty kilodaltons corresponding to pyruvate kinase M. Although vIRF3 could bind both the PKM1 and PKM2 isoforms in pull-down assays, only PKM2 was expressed in lymphatic endothelial cells, so the investigators focused their attention on the vIRF3–PKM2 axis. Detailed binding experiments mapped the interaction to a short region of vIRF3 spanning amino acids 250 to 280. Deleting this segment produced a mutant viral protein, vIRF3-MT, that lost the ability to bind PKM2 while retaining its interactions with other known partners, including IRF7, HIF1α and HDAC5, making it a clean genetic tool for isolating the metabolic consequences of the interaction.

The biological significance of the binding became apparent when the researchers examined the oligomeric state of PKM2. This enzyme exists in two functionally distinct forms: a tetramer that acts as an active pyruvate kinase, channeling carbon from phosphoenolpyruvate into pyruvate and onward into the tricarboxylic acid cycle, and a nuclear dimer that functions as a transcriptional co-factor supporting aerobic glycolysis. When wild-type vIRF3 was expressed in lymphatic endothelial cells, cross-linking experiments showed a striking increase in PKM2 tetramerization, accompanied by elevated pyruvate kinase activity, higher intracellular acetyl coenzyme A levels and reduced lactate concentrations. The mutant viral protein, lacking the PKM2-binding region, produced none of these effects. Seahorse metabolic flux analysis reinforced the picture: cells expressing wild-type vIRF3 showed significantly increased oxygen consumption rates, including higher basal respiration, ATP production and maximal respiratory capacity, while their extracellular acidification rate, a proxy for glycolysis, declined.

To trace where the newly abundant acetyl-CoA came from, the team performed liquid chromatography–mass spectrometry metabolomics and isotope tracing with uniformly labeled carbon-13 glucose. In cells expressing wild-type vIRF3, pyruvate accumulated predominantly in the M+3 isotopologue form, a signature of enhanced PKM2 activity, and the labeled carbon flowed into M+1 and M+2 acetyl-CoA, which then fed the biosynthesis of citrate, α-ketoglutarate, succinate, fumarate and malate. Glutamate labeling patterns indicated that the cells were not relying on glutaminolysis to replenish the cycle, and measurements of fatty acid oxidation intermediates showed that this pathway was actually suppressed: carnitine accumulated while expression of carnitine palmitoyltransferase 1A and downstream β-oxidation intermediates fell. The evidence therefore pointed to enhanced pyruvate catabolism, rather than fatty acid oxidation or glutamine metabolism, as the principal source of the expanded acetyl-CoA pool.

Acetyl-CoA is not merely a fuel; it donates acetyl groups for the lysine acetylation of thousands of proteins, including transcription factors. Consistent with this, wild-type vIRF3 expression raised the global acetylation level of cellular proteins, and this increase depended on citrate exported from mitochondria and processed by ATP citrate lyase, since the ACLY inhibitor BMS-303141 abolished the effect. A human protein acetylation microarray then identified twenty-four proteins whose acetylation rose specifically in the presence of the vIRF3–PKM2 interaction. Among them, the investigators prioritized SMAD5, a transcriptional effector of TGFβ–BMP signaling with established roles in endothelial-to-mesenchymal transition, the process by which endothelial cells lose their identity and acquire invasive, mesenchymal characteristics.

Immunoprecipitation confirmed that SMAD5 acetylation was markedly increased in cells expressing wild-type vIRF3 but not the binding-defective mutant, and co-immunoprecipitation identified the acetyltransferase p300 as the enzyme responsible, since the p300 inhibitor A-485 reduced SMAD5 acetylation. The functional consequences were dramatic. Cells expressing wild-type vIRF3 adopted a spindle-shaped, mesenchymal morphology, downregulated the endothelial markers LYVE-1 and VE-cadherin, and upregulated mesenchymal markers including vimentin, fibronectin, N-cadherin and α-smooth muscle actin. Three-dimensional spheroid invasion assays in Matrigel and Boyden chamber migration assays demonstrated that these behaviors depended on SMAD5: silencing SMAD5 with short hairpin RNAs abolished both the invasive growth and the migration induced by vIRF3.

Critical controls established that this metabolic hijacking is separable from the viral life cycle itself. Using bacterial artificial chromosome-based recombination, the team constructed recombinant KSHV clones carrying either wild-type vIRF3, the Δ250-280 deletion mutant, or a revertant restoring the wild-type sequence. The mutant virus replicated normally, produced comparable infectious virions and expressed latent and lytic genes at levels indistinguishable from wild type. Yet when lymphatic endothelial cells were infected with these viruses, only wild-type and revertant infections raised pyruvate kinase activity and acetyl-CoA levels, drove spheroid invasion, and enabled colony formation in soft agar. The phenotypes were reproduced in primary human lymphatic endothelial cells, confirming that the metabolic reprogramming is a genuine consequence of KSHV infection rather than an artifact of immortalized cell lines.

The in vivo consequences were equally striking. In xenograft experiments with immunodeficient NCr-nu/nu mice, cells infected with wild-type or revertant KSHV formed tumors efficiently, whereas cells infected with the vIRF3-MT virus did not. Moreover, mice bearing wild-type-derived tumors developed secondary lesions in the stomach, spleen and liver that displayed hallmark histopathological features of Kaposi’s sarcoma, including extravasated erythrocytes, hemosiderin deposits and spindle-shaped cells positive for the viral latency antigen LANA, vIRF3, the endothelial marker CD31 and the lymphatic lineage factor PROX1. Human vimentin-positive cells at these sites traced back to the implanted infected endothelial cells. No secondary tumors appeared in mice injected with the PKM2-binding-defective virus, directly implicating the vIRF3–PKM2 interaction in disseminated visceral disease.

The study also delivers a potential therapeutic lead. Because amino acids 250 to 260 of vIRF3 were sufficient for PKM2 binding, the researchers designed a short vIRF3-derived peptide, termed VDP, fused to the HIV TAT transduction domain for intracellular delivery. VDP competed with vIRF3 for PKM2 binding, blocked vIRF3-induced PKM2 tetramerization and enzymatic activity, and lowered acetyl-CoA and ATP levels, while a binding-defective mutant peptide, mVDP, did none of these things. Structural modeling with AlphaFold-Multimer and molecular dynamics simulations showed VDP occupying the intersubunit interface of PKM2, and biolayer interferometry measured a dissociation constant of 1.28 micromolar, roughly twenty-nine-fold tighter than the mutant peptide. In chick embryo chorioallantoic membrane assays, TAT-VDP suppressed vIRF3-driven invasion into the endoderm layer, and in xenograft mice the peptide markedly inhibited tumor formation and regressed established tumors without substantial toxicity.

The authors caution that the vIRF3–PKM2–acetyl-CoA–SMAD5 axis still requires validation in patient-derived Kaposi’s sarcoma tissues, which have been difficult to obtain in adequately preserved form, and that their xenograft model does not distinguish true metastatic dissemination from other routes of systemic distribution. Even so, the work provides the most complete mechanistic account to date of how an oncogenic herpesvirus converts a host metabolic enzyme into an engine of tumor progression, linking acetyl-CoA flux through the TCA cycle to epigenetic modification of a developmental transcription factor. By demonstrating that a rationally designed viral peptide can reverse this process in living animals, the study positions PKM2 not merely as a metabolic marker but as an actionable target for treating disseminated Kaposi’s sarcoma.

Subject of Research: KSHV vIRF3–PKM2 interaction, acetyl-CoA metabolic reprogramming and SMAD5 acetylation in Kaposi's sarcoma progression

Article Title: KSHV vIRF3–PKM2 interaction induces SMAD5 acetylation, promoting Kaposi’s sarcoma progression

Article References: Kim, Y. J., Lim, J., Lee, J. J., Kumar, A., Kannappan, S., Zhang, J., Kim, S., Kim, H.-J., Kim, K. K., Toth, Z., Eoh, H., Choi, K.-C., & Lee, H.-R. (2026). KSHV vIRF3–PKM2 interaction induces SMAD5 acetylation, promoting Kaposi’s sarcoma progression. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01849-2

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01849-2

Keywords: KSHV, Kaposi's sarcoma, vIRF3, PKM2, acetyl-CoA, SMAD5 acetylation, lymphatic endothelial cells, endothelial-to-mesenchymal transition, metabolic reprogramming, p300, TCA cycle, therapeutic peptide

The study, published in PLOS Pathogens by Yu Zhang, Peng Wang and colleagues at the People’s Hospital of Xinjiang Uygur Autonomous Region, focused on the viral gene K15, which sits at the right end of the KSHV genome and encodes a multi-pass transmembrane signaling protein. K15 exists in two highly divergent alleles, known as the prototype (P) and minority (M) forms. In their cytoplasmic signaling domains, the two variants share less than 33 percent amino acid homology, a degree of divergence that suggests they may engage different molecular partners inside infected cells and, potentially, shape disease in different ways.

Xinjiang, a historical crossroads on the Silk Road, offered an unusually informative setting. The region has a high prevalence of Kaposi sarcoma and co-circulating viral genotypes rarely seen together in Western cohorts. Of the 147 patients who passed quality control and genotyping, 107, or 72.8 percent, carried the K15M variant, while 40 carried K15P. That distribution echoes patterns reported in classic Kaposi sarcoma cohorts from Japan and Taiwan and hints that host genetic and evolutionary pressures in Central Asian populations may have favored the M form.

The clinical picture that emerged was striking and, at first glance, paradoxical. Patients carrying the M genotype were significantly less likely to be coinfected with HIV, at 10.3 percent versus 27.5 percent among P carriers, yet they showed higher levels of systemic inflammation, measured by the Systemic Immune-Inflammation Index (SII), the neutrophil-to-lymphocyte ratio, and neutrophil counts. They also suffered lower limb edema far more often, at 37.4 percent versus 20.0 percent, and were less likely to have mucosal involvement. After adjusting for tumor stage, demographics and CD4 T-cell counts, K15M carriage remained an independent predictor of edema, with 2.6-fold increased odds, and of a high inflammatory burden, with an adjusted odds ratio of 5.43 for elevated SII.

To probe whether inflammation actually lies on the causal path between viral genotype and edema, the team used causal mediation analysis, a statistical framework that decomposes an association into direct and indirect components. The Systemic Immune-Inflammation Index significantly mediated 29.0 percent of the genotype-associated effect on edema, with a P value of 0.009. A reverse mediation model, testing whether edema led to inflammation rather than the other way around, failed to reach significance, supporting inflammation’s position upstream in the pathway. Dose-response analysis sharpened the picture further: among K15M carriers, edema risk rose linearly with increasing SII, with an odds ratio of 1.58 per 500-unit increase, whereas no such gradient existed in K15P carriers. The inflammation-edema link, in other words, appears intrinsically tied to the viral genotype.

The mechanistic plausibility rests on the structure of the K15 protein. Its signaling capacity resides in a C-terminal cytoplasmic tail containing SH2- and SH3-binding motifs that recruit Src-family kinases and TRAF adaptor proteins to activate the pro-inflammatory NF-kB and MAPK pathways. The P form has been well characterized as mobilizing these cascades through specific tyrosine-based motifs. The M form, by contrast, shows reduced dependence on the canonical YEEV motif for NFAT activation, and the authors hypothesize that its structurally distinct tail may confer enhanced affinity for inflammatory adaptors or lack the negative regulatory phosphorylation sites present in the P type. Such differences could produce constitutive, unchecked signaling that sustains high-grade systemic inflammation, which in turn promotes vascular permeability and the tissue swelling that clinicians observe as edema.

The genotype also carried prognostic weight. Kaplan-Meier analysis showed significantly inferior progression-free survival among K15M carriers, with a log-rank P value of 0.017, and multivariate Cox modeling yielded an adjusted hazard ratio of 1.87, a borderline but robust estimate confirmed across multiple censoring scenarios in sensitivity analyses. Notably, the deleterious effect was most pronounced in patients with localized disease, where the hazard ratio reached 4.32, suggesting that viral biology can flag danger even when the tumor appears anatomically confined. A dedicated sensitivity analysis restricted to classic Kaposi sarcoma patients preserved the inflammatory signature of K15M, arguing against clinical subtype as a confounder.

To convert these biological insights into a usable clinical instrument, the researchers built a six-factor prognostic nomogram using LASSO Cox regression with cross-validation, maintaining an events-per-variable ratio of 11.2. The model anchors on the K15 genotype and visceral involvement, supplemented by CD4 count, procalcitonin, the lymphocyte-to-monocyte ratio and the neutrophil-to-lymphocyte ratio, the latter two selected over SII to avoid collinearity. The tool achieved a concordance index of 0.761, corrected to 0.743 after bootstrapping with 5,000 resamples, and time-dependent ROC analysis showed areas under the curve above 0.80 at one, two and three years.

The head-to-head comparison with conventional staging was decisive. The nomogram achieved an area under the curve of 0.830, significantly outperforming anatomical stage alone at 0.563 and visceral involvement alone at 0.530, with P values of 0.003 and below 0.001 respectively. Reclassification metrics confirmed substantial gains in predictive accuracy, and decision curve analysis demonstrated net clinical benefit across a wide range of threshold probabilities. When patients were stratified by nomogram score, the high-risk group showed a median progression-free survival of 11.0 months versus 40.0 months in the low-risk group, a separation with a P value below 0.0001 that held regardless of HIV status or tumor burden.

The authors are careful to frame their conclusions within the limits of a single-center, retrospective design. Edema was assessed qualitatively rather than with quantitative metrics, a small fraction of viral genotypes remained unclassified, possibly reflecting recombination or untyped variants, and the mediation results are presented as biologically plausible associations rather than definitive causal proof, since no wet-lab cytokine assays were performed on the archival samples. Even so, the implications are considerable. If the K15M genotype sustains an NF-kB-driven inflammatory program independent of immunodeficiency, then carriers may represent a subgroup amenable to anti-inflammatory or immunomodulatory strategies layered onto conventional therapy, with genotyping serving as a companion diagnostic. More broadly, the study argues that Kaposi sarcoma risk assessment should move from anatomical observation toward biology-driven precision oncology, incorporating the genetics of the virus itself into the clinical calculus, particularly in regions where the M genotype predominates.

Subject of Research: Association of KSHV K15 genetic variants with Kaposi sarcoma aggressiveness and inflammation

Article Title: KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment

Article References: Zhang, Y., Wang, P., Zhang, J., Wang, Y., Li, T., Ding, Y., & Kang, X. (2026). KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment. PLOS Pathogens, 22(10), e1014615. https://doi.org/10.1371/journal.ppat.1014615

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014615

Keywords: KSHV, Kaposi sarcoma, K15 genotype, inflammation, herpesvirus, edema, prognostic nomogram, precision oncology, mediation analysis, NF-kB, HIV, viral genotyping

Chaperone-mediated autophagy, or CMA, is distinct from the better-known bulk-recycling form of autophagy. Instead of engulfing entire cellular structures in membrane-bound vesicles, CMA operates one protein at a time. Cytoplasmic proteins carrying a specific pentapeptide recognition motif are bound by the chaperone HSC70 and delivered to the lysosomal membrane, where LAMP2A acts as the receptor. The substrate protein then unfolds and threads through a multimeric channel formed by LAMP2A molecules into the lysosomal lumen, where it is degraded. Because this pathway can selectively remove transcription factors, metabolic enzymes and signaling proteins, it has long been implicated in cancer progression, immune regulation and aging, yet how pathogens manipulate it has remained poorly understood.

The new work began with a proteomic search for proteins that associate with TRIM32, a member of the tripartite motif family of E3 ligases, during KSHV infection. Using mass spectrometry on purified TRIM32 complexes from infected cells, the researchers found that TRIM32 interacted prominently with components of the CMA machinery, including HSC70, HSP90 and LAMP2A itself. Gene ontology analysis of the interactors confirmed enrichment in chaperone-mediated autophagy and innate immune pathways. When cells were stimulated with double-stranded DNA, a molecular stand-in for viral DNA sensing, TRIM32 formed visible cytoplasmic bodies that co-localized with LAMP2A and other CMA components, and the physical interaction between TRIM32 and LAMP2A could be recapitulated with purified recombinant proteins in vitro.

The pivotal discovery concerned a post-translational modification known as SUMOylation, in which small ubiquitin-like modifier proteins, chiefly SUMO2 and SUMO3, are covalently attached to lysine residues on target proteins. SUMOylation is reversible and frequently alters a protein’s localization, interaction partners or stability, and it has well-documented roles in both viral infection and tumorigenesis. The team showed that TRIM32 acts as a SUMO E3 ligase for LAMP2A, conjugating SUMO2/3 to three specific lysines: K104, K132 and K289. Detailed mapping experiments revealed that K289 and K104 serve as primary sites for SUMO2 attachment, while a SUMO-interacting motif on LAMP2A, SIM1, facilitates SUMO3 modification at K132. The RING domain of TRIM32 proved essential for this modification.

What makes this modification so consequential is where it sends LAMP2A. Although LAMP2A is classically viewed as a lysosomal membrane receptor, the study found that SUMOylated LAMP2A accumulates in the nucleus during viral infection. This nuclear translocation of LAMP2A, driven by TRIM32-dependent SUMOylation, activates the CMA program, allowing the infected cell to selectively degrade a distinct set of client proteins. Among the consequences documented in the paper is the suppression of viral reactivation and inflammation: by keeping the lytic program damped down, the virus preserves latency, its long-term persistence strategy, while the altered cellular environment simultaneously favors tumor growth and the formation of new blood vessels, a process called angiogenesis.

Using KSHV as a model system, the researchers demonstrated in animal models that TRIM32-induced SUMOylation of LAMP2A promotes tumor growth and angiogenesis in vivo. When LAMP2A was depleted from KSHV-transformed cells, TRIM32’s ability to drive colony formation and xenograft expansion collapsed. Reconstituting the cells with wild-type LAMP2A restored tumorigenesis, but reconstitution with SUMOylation-defective mutants, in which the key lysines were changed to arginine, failed to do so. Immunohistochemical staining of the resulting tumors showed corresponding changes in markers of proliferation, endothelial content and viral lytic reactivation, tying the molecular modification directly to pathological outcomes.

Crucially, the mechanism appears not to be a quirk of KSHV alone. In tumor tissues from patients, the team found that TRIM32 expression positively correlates with LAMP2A in cancers associated with KSHV, Epstein–Barr virus and human papillomavirus, the viruses behind Kaposi’s sarcoma, nasopharyngeal carcinoma and cervical cancer, respectively. The correlation was stratified by the abundance of viral latent antigens such as LANA, EBNA1 and E6, suggesting that the burden of latent viral infection tracks with activation of this CMA-regulating axis. A pan-cancer analysis using the GEPIA database further showed coordinated TRIM32 and LAMP2A expression across a range of tumor types, hinting that the pathway may extend beyond classic tumor viruses.

Perhaps the most translationally exciting aspect of the study is the development of peptide inhibitors that target the SUMOylated form of LAMP2A. Derived from LAMP2A sequences, the peptides P3 and P7 were designed to disrupt the SUMOylation-dependent nuclear localization and function of the receptor. In cell culture, the peptides suppressed colony formation by KSHV-, EBV- and HPV-infected cancer cells at concentrations that showed minimal cytotoxicity toward uninfected cells. In mouse xenograft models, including both subcutaneous and intraperitoneal tumor systems, treatment with the peptides reduced tumor progression and angiogenesis. The antitumor effect depended on intact LAMP2A and SUMO2: the peptides lost efficacy in cells lacking LAMP2A or with SUMO2 knocked out, and in cells reconstituted with SUMOylation-site mutants, confirming that the drugs act precisely on the pathway the team had dissected.

The work also clarifies a long-standing puzzle about how oncogenic viruses balance two competing needs. Reactivating into the lytic cycle produces new viral particles but exposes the infection to immune detection and inflammatory stress, whereas permanent latency forgoes transmission. By activating CMA through SUMOylated LAMP2A, the virus appears to buy itself a stable middle ground: lytic genes stay quiet, inflammatory signaling is blunted, and the host cell survives long enough to accumulate the mutations and vascular support that a tumor requires. Earlier studies had shown that CMA is required for tumor growth and that LAMP2A is overexpressed in several malignancies, but the viral trigger and the specific enzymatic machinery, TRIM32 acting on defined lysines, had not previously been connected.

For patients with virus-associated cancers, the implications are significant. Current treatments for Kaposi’s sarcoma and related malignancies often rely on broad chemotherapy or immune modulation, and options specifically targeting the virus–host interface remain limited. A receptor like LAMP2A, positioned at the convergence of viral persistence and tumor maintenance, offers a single point of intervention with dual antiviral and antitumor potential. The peptide approach also demonstrates that blocking a specific post-translational modification, rather than the entire autophagy pathway, can achieve therapeutic selectivity, an important consideration given CMA’s normal roles in neurons, liver and immune cells. The authors have filed a provisional patent on the compositions and methods, and while peptide drugs face delivery and stability hurdles before clinical use, the study establishes LAMP2A SUMOylation as a promising and mechanistically well-defined target. As oncogenic viruses continue to account for a substantial share of cancers worldwide, understanding and interrupting the molecular hijacking they perform may prove one of the most consequential strategies in virology-driven cancer therapy.

Subject of Research: How oncogenic viral infection drives LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis

Article Title: Oncogenic viral infection triggers LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis

Article References: Oncogenic viral infection triggers LAMP2A SUMOylation and chaperone-mediated autophagy to promote tumorigenesis. (n.d.). https://doi.org/10.1038/s41564-026-02476-3

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02476-3

Keywords: KSHV, LAMP2A, TRIM32, SUMOylation, chaperone-mediated autophagy, oncogenic viruses, tumorigenesis, angiogenesis, Epstein-Barr virus, human papillomavirus, virus-host interactions, peptide inhibitors